● Recruiting

A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

Condition: Urinary Bladder Cancer · Invasive Bladder Cancer · Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

PhasePhase 1/Phase 2

Planned participants50

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

A multicenter Phase 1b/2, two stage, open label study of MMC/Capecitabine ChRT combined with nivolumab monotherapy or nivolumab and ipilimumab combination therapy in adult (\>18 years) subjects with non-metastatic muscle invasive bladder cancer that qualify for ChRT with curative intent.

This description comes directly from the study's public registry record.

Talk to the study team

Adriaan D. Bins, MD PhD · 0205662339 · a.d.bins@amc.uva.nl

Always discuss trial participation with your own doctor first.

Locations (3)

Amsterdam UMC, VUmc	Amsterdam, North Holland, Netherlands	Recruiting
Amsterdam UMC, AMC	Amsterdam, North Holland, Netherlands	Recruiting
LUMC	Leiden, South Holland, Netherlands	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03844256